Adis Journals
Selpercatinib Plain Language Summary.pdf (240.5 kB)

Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC

Download (240.5 kB)
online resource
posted on 2022-11-23, 22:37 authored by Tina Nie, Yahiya Y. Syed


Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest Tina Nie and Yahiya Y. Syed are salaried employees of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here 


Selpercatinib (Retevmo®/Retsevmo®) is an orally-administered, selective inhibitor of rearranged during transfection (RET) kinase approved for the treatment of advanced RET fusion-positive non-small cell lung cancer (NSCLC). In a pivotal phase 1/2 clinical trial in this population, selpercatinib treatment was associated with robust and durable responses, including intracranial responses, in patients previously treated with platinum-based chemotherapy, as well as in treatment-naïve patients. Selpercatinib had a manageable tolerability profile and an acceptable safety profile; adverse events could generally be managed with dose reductions and only a small proportion of patients discontinued selpercatinib due to treatment-related adverse events. The most common treatment-related adverse events that were grade 3–4 in severity were hypertension, elevated alanine aminotransferase and elevated aspartate aminotransferase. Thus, currently available evidence suggests that selpercatinib is a promising new RET-targeted therapy option for patients with advanced RET fusion-positive NSCLC.

 © Springer Nature Switzerland AG 2022


Usage metrics

    Targeted Oncology



    Ref. manager